Aclaris Therapeutics Inc (ACRS) Unusual Options Activity Today

Checking ACRS unusual options activity helps you spot when traders are making outsized bets on Aclaris Therapeutics Inc before the broader market catches on. Aclaris Therapeutics Inc's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor ACRS unusual options activity today and surface the prints that deserve a second look.

Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching ACRS unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking ACRS unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and ACRS unusual options flow data becomes especially valuable around earnings, product launches, and macro events.

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis.

In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Catalysts rarely arrive without a footprint, and ACRS unusual options activity is often where that footprint shows up first. Our scanner tracks Aclaris Therapeutics Inc's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at ACRS unusual options volume on the call side or chasing put sweeps, Aclaris Therapeutics Inc's unusual options flow today is one click away, so put it on your radar before the headlines hit.